Botanix Pharmaceuticals Limited (ASX:BOT)
Australia · Delayed Price · Currency is AUD 0.0200
+0.0010 (5.26%)
Sep 11, 2026, 12:04 PM AEST
Botanix Pharmaceuticals Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 36.63 | 64.97 | 79.31 | 10.25 | 7.29 |
Cash & Short-Term Investments | 36.63 | 64.97 | 79.31 | 10.25 | 7.29 |
Cash Growth | -43.61% | -18.08% | 673.71% | 40.69% | -66.20% |
Accounts Receivable | 5.97 | 2.85 | 0.46 | 0.4 | - |
Other Receivables | 0.67 | 0.35 | 0.36 | 0.09 | 0.14 |
Receivables | 6.64 | 3.2 | 0.82 | 0.49 | 0.14 |
Inventory | 31.35 | 28.08 | 1.21 | 3.15 | 3.04 |
Prepaid Expenses | 5.65 | 3.34 | 0.1 | 0.09 | 0.03 |
Other Current Assets | - | - | 1.47 | - | - |
Total Current Assets | 80.28 | 99.59 | 82.9 | 13.98 | 10.5 |
Property, Plant & Equipment | 0.82 | 1.38 | 0.07 | 0.07 | 0.18 |
Other Intangible Assets | 24.88 | 28.12 | 29.49 | 6.86 | 3.3 |
Long-Term Deferred Charges | - | - | - | 3.87 | - |
Other Long-Term Assets | - | - | - | 0.06 | 0.06 |
Total Assets | 105.98 | 129.1 | 112.46 | 24.84 | 14.04 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 5.86 | 8.87 | 2.73 | 1.39 | 4.68 |
Accrued Expenses | 6.29 | 3.94 | 0.56 | 0.15 | 0.1 |
Current Portion of Leases | 0.47 | 0.41 | - | - | 0.12 |
Other Current Liabilities | 18.36 | 11.7 | 0.44 | 0.34 | 0.99 |
Total Current Liabilities | 30.98 | 24.92 | 3.73 | 1.88 | 5.89 |
Long-Term Leases | 0.45 | 0.81 | - | - | - |
Other Long-Term Liabilities | 11.03 | 22.07 | - | - | - |
Total Liabilities | 42.45 | 47.8 | 3.73 | 1.88 | 5.89 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 268.26 | 226.3 | 188.32 | 93.49 | 71.48 |
Retained Earnings | -246.96 | -177.19 | -90.79 | -76.92 | -67.77 |
Comprehensive Income & Other | 42.22 | 32.18 | 11.2 | 6.38 | 4.44 |
Shareholders' Equity | 63.52 | 81.3 | 108.73 | 22.95 | 8.15 |
Total Liabilities & Equity | 105.98 | 129.1 | 112.46 | 24.84 | 14.04 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.92 | 1.22 | - | - | 0.12 |
Net Cash (Debt) | 35.71 | 63.75 | 79.31 | 10.25 | 7.16 |
Net Cash Growth | -43.98% | -19.62% | 673.71% | 43.10% | -66.36% |
Net Cash Per Share | 0.02 | 0.03 | 0.05 | 0.01 | 0.01 |
Filing Date Shares Outstanding | 2,737 | 1,961 | 1,814 | 1,421 | 1,085 |
Total Common Shares Outstanding | 2,734 | 1,961 | 1,810 | 1,312 | 973.14 |
Working Capital | 49.3 | 74.67 | 79.17 | 12.09 | 4.62 |
Book Value Per Share | 0.02 | 0.04 | 0.06 | 0.02 | 0.01 |
Tangible Book Value | 38.64 | 53.17 | 79.24 | 16.1 | 4.86 |
Tangible Book Value Per Share | 0.01 | 0.03 | 0.04 | 0.01 | 0.00 |